• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对纯抗雌激素耐药的人乳腺癌细胞系对他莫昔芬治疗敏感。

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.

作者信息

Lykkesfeldt A E, Larsen S S, Briand P

机构信息

Department of Tumor Endocrinology, Danish Cancer Society, Copenhagen.

出版信息

Int J Cancer. 1995 May 16;61(4):529-34. doi: 10.1002/ijc.2910610417.

DOI:10.1002/ijc.2910610417
PMID:7759159
Abstract

The pure steroidal anti-estrogens ICI 164,384 and ICI 182,780 are very potent growth inhibitors of the estrogen receptor-positive human breast cancer cell line MCF-7. However, long-term treatment of MCF-7 cells with 10(-7) M concentrations of these compounds results in selection of proliferating colonies of resistant cells. Our report describes 4 ICI 164,384- and 3 ICI 182,780-resistant MCF-7 sublines established after long-term treatment. Resistant sublines are estrogen receptor-positive, and all sublines have lost expression and estrogen inducibility of the progesterone receptor protein. Based on IC50 concentrations, all tested resistant sublines had a reduced sensitivity to pure anti-estrogens on the order of 100- to 1000-fold compared with parent MCF-7 cells. All resistant cell lines have survived propagation for more than 15 subcultivations in the presence of 10(-7) M pure anti-estrogen. The MCF-7/182R-6 subline has been tested for stability of resistance and appeared to be stably resistant after 13 weeks of propagation without the selective pressure of ICI 182,780. Cell lines resistant to the ICI 182,780 compound are cross-resistant to the ICI 164,384 compound and vice versa. However, the sublines resistant to pure antiestrogens are sensitive to tamoxifen. Our results show that although the pure steroidal anti-estrogens are very potent growth inhibitors, they do not circumvent development of resistance.

摘要

纯甾体类抗雌激素药物ICI 164,384和ICI 182,780是雌激素受体阳性的人乳腺癌细胞系MCF - 7非常有效的生长抑制剂。然而,用10(-7) M浓度的这些化合物对MCF - 7细胞进行长期处理会导致耐药细胞增殖集落的选择。我们的报告描述了长期处理后建立的4个对ICI 164,384耐药和3个对ICI 182,780耐药的MCF - 7亚系。耐药亚系为雌激素受体阳性,所有亚系均丧失了孕激素受体蛋白的表达及雌激素诱导性。根据半数抑制浓度(IC50),与亲代MCF - 7细胞相比,所有测试的耐药亚系对纯抗雌激素的敏感性降低了100至1000倍。所有耐药细胞系在10(-7) M纯抗雌激素存在下已传代培养超过15次仍存活。MCF - 7/182R - 6亚系已测试耐药稳定性,在没有ICI 182,780选择压力的情况下传代培养13周后似乎仍稳定耐药。对ICI 182,780化合物耐药的细胞系对ICI 164,384化合物交叉耐药,反之亦然。然而,对纯抗雌激素耐药的亚系对他莫昔芬敏感。我们的结果表明,尽管纯甾体类抗雌激素是非常有效的生长抑制剂,但它们并不能避免耐药性的产生。

相似文献

1
Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment.对纯抗雌激素耐药的人乳腺癌细胞系对他莫昔芬治疗敏感。
Int J Cancer. 1995 May 16;61(4):529-34. doi: 10.1002/ijc.2910610417.
2
Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.雌激素调节基因在他莫昔芬耐药以及对ICI 164,384和ICI 182,780敏感的人乳腺癌细胞系MCF-7/TAMR-1中的表达改变。
Cancer Res. 1994 Mar 15;54(6):1587-95.
3
Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells.ICI 164,384和ICI 182,780对4-羟基他莫昔芬耐药的人乳腺癌细胞的抗增殖和抗雌激素作用
Int J Cancer. 1994 Jan 15;56(2):295-300. doi: 10.1002/ijc.2910560225.
4
Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness.人类乳腺癌细胞对纯甾体抗雌激素ICI 182,780的耐药性与雌激素受体表达的普遍丧失或雌激素反应性的缺乏无关。
Int J Cancer. 1997 Sep 17;72(6):1129-36. doi: 10.1002/(sici)1097-0215(19970917)72:6<1129::aid-ijc31>3.0.co;2-x.
5
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.在人乳腺癌模型中,纯甾体类抗雌激素与他莫昔芬的效果比较。
J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746.
6
Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.4-羟基他莫昔芬及新型纯抗雌激素药物(ICI 182780)对人乳腺癌细胞体外克隆生长的影响
Br J Cancer. 1994 Aug;70(2):204-11. doi: 10.1038/bjc.1994.281.
7
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.MCF7/LCC9:一种抗雌激素的MCF-7变体,其中对甾体抗雌激素ICI 182,780获得性耐药赋予了对非甾体抗雌激素他莫昔芬的早期交叉耐药性。
Cancer Res. 1997 Aug 15;57(16):3486-93.
8
Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.纯抗雌激素ICI 182,780对他莫昔芬耐药性的规避
Int J Cancer. 1993 Nov 11;55(5):873-6. doi: 10.1002/ijc.2910550529.
9
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.MCF7/LCC2:一种对4-羟基他莫昔芬耐药但对甾体类抗雌激素ICI 182,780仍敏感的人乳腺癌变体。
Cancer Res. 1993 Jul 15;53(14):3229-32.
10
Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells.他莫昔芬和ICI 182,780对MCF-7人乳腺癌细胞阿霉素耐药性的调节作用。
Int J Cancer. 1996 Nov 4;68(3):340-8. doi: 10.1002/(SICI)1097-0215(19961104)68:3<340::AID-IJC12>3.0.CO;2-C.

引用本文的文献

1
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.雌激素受体靶向治疗诱导TEAD共激活因子VGLL1导致乳腺癌耐药。
Cancer Res. 2024 Dec 16;84(24):4283-4297. doi: 10.1158/0008-5472.CAN-24-0013.
2
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.联合 CDK4/6 和 AKT 靶向治疗联合内分泌治疗可预防 CDK4/6 抑制剂和内分泌治疗耐药性乳腺癌的进展。
Nat Commun. 2021 Aug 25;12(1):5112. doi: 10.1038/s41467-021-25422-9.
3
Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.
乳腺癌诊断、治疗与诊疗一体化的现状
Pharmaceutics. 2021 May 14;13(5):723. doi: 10.3390/pharmaceutics13050723.
4
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.MCM3上调赋予乳腺癌内分泌抗性,并且是他莫昔芬获益减少的预测标志物。
NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8.
5
Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.缺氧诱导因子-1α 的表达与对侧乳腺癌不良预后和他莫昔芬耐药有关。
PLoS One. 2019 Dec 10;14(12):e0226150. doi: 10.1371/journal.pone.0226150. eCollection 2019.
6
Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.组蛋白甲基转移酶 DOT1L 的抑制沉默 ERα 基因并阻断抗雌激素耐药乳腺癌细胞的增殖。
Sci Adv. 2019 Feb 6;5(2):eaav5590. doi: 10.1126/sciadv.aav5590. eCollection 2019 Feb.
7
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence.氟维司群在乳腺癌治疗中的临床应用:关于新出现临床证据的报告。
Cancer Manag Res. 2018 Aug 30;10:3083-3099. doi: 10.2147/CMAR.S137772. eCollection 2018.
8
Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.SUMOylation 在乳腺癌细胞中他莫昔芬和氟维司群对 ERα 转录抑制的差异中的作用。
Oncogene. 2019 Feb;38(7):1019-1037. doi: 10.1038/s41388-018-0468-9. Epub 2018 Sep 6.
9
A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382.RelA/p65调控的miR-22通过靶向FOXP1和HDAC4以及p53在赖氨酸382位点的组成型乙酰化,在使氟维司群耐药的乳腺癌细胞对氟维司群重新敏感化中发挥双重作用。
Oncogenesis. 2018 Jul 30;7(7):54. doi: 10.1038/s41389-018-0063-5.
10
SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.SNAI2 上调与氟维司群耐药乳腺癌细胞的侵袭表型相关,是雌激素受体阳性转移性乳腺癌内分泌治疗反应不良的标志。
Breast Cancer Res. 2018 Jun 19;20(1):60. doi: 10.1186/s13058-018-0988-9.